TEP RNA: a new frontier for early diagnosis of NSCLC
Open Access
- 19 February 2024
- journal article
- review article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 150 (2) , 1-15
Abstract
Background: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer (LC), which is the leading cause of tumor mortality. In recent years, compared with tissue biopsy, which is the diagnostic gold standard for tumor diagnosis, Liquid biopsy (LB) is considered to be a more minimally invasive, sensitive, and safer alternative or auxiliary diagnostic method. However, the current value of LB in early diagnosis of LC is not ideal, so it is particularly important to study the changes in blood composition during the process of tumorigenesis and find more sensitive biomarkers. Purpose: Platelets are a type of abundant blood cells that carry a large amount of RNA. In the LC regulatory network, activated platelets play an important role in the process of tumorigenesis, development, and metastasis. In order to identify predictive liquid biopsy biomarkers for the diagnosis of NSCLC, we summarized the development and function of platelets, the interaction between platelets and tumors, the value of TEP RNA in diagnosis, prognosis, and treatment of NSCLC, and the method for detecting TEP RNA of NSCLC in this article. Conclusion: The application of platelets in the diagnosis and treatment of NSCLC remains at a nascent stage. In addition to the drawbacks of low platelet count and complex experimental processes, the diagnostic accuracy of TEP RNA-seq for cancer in different populations still needs to be improved and validated. At present, a large number of studies have confirmed significant differences in the expression of TEP RNA in platelets between NSCLC patients and healthy individuals. Continuous exploration of the diagnostic value of TEP RNA in NSCLC is of utmost importance. The integration of NSCLC platelet-related markers with other NSCLC markers can improve current tumor diagnosis and prognostic evaluation systems, providing broad prospects in tumor screening, disease monitoring, and prognosis assessment.Keywords
Funding Information
- Natural Science Foundation of Shandong Province (No. ZR2023QC072)
This publication has 115 references indexed in Scilit:
- Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapyCancer Immunology, Immunotherapy, 2023
- Gene signature of circulating platelet‐bound neutrophils is associated with poor prognosis in cancer patientsInternational Journal of Cancer, 2022
- TEP linc-GTF2H2-1, RP3-466P17.2, and lnc-ST8SIA4-12 as novel biomarkers for lung cancer diagnosis and progression predictionJournal of Cancer Research and Clinical Oncology, 2021
- A three-platelet mRNA set: MAX, MTURN and HLA-B as biomarker for lung cancerJournal of Cancer Research and Clinical Oncology, 2019
- Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small‐cell lung cancer treated with nivolumabJournal of Clinical Laboratory Analysis, 2019
- Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancerJournal of Cancer Research and Clinical Oncology, 2019
- Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patientsJournal of Cancer Research and Clinical Oncology, 2015
- A Rapid and Efficient Platelet Purification Protocol for Platelet Gene Expression Studies2011
- Platelet proteomicsMass Spectrometry Reviews, 2011
- Differential expression of platelet‐derived growth factor and transforming growth factor genes in small‐ and non‐small‐cell human lung carcinoma linesInternational Journal of Cancer, 1988